Pyxis Oncology Announces Participation in Leerink Global Biopharma Conference 2024

BOSTON, March 07, 2024 -- Pyxis Oncology, Inc. PYXS, a company at the forefront of developing innovative therapeutics for hard-to-treat cancers, has recently made an announcement concerning its participation in the upcoming Leerink Global Biopharma Conference of 2024. Lara S. Sullivan, M.D., the President and Chief Executive Officer of Pyxis Oncology, is scheduled to represent the company at this distinguished event.

Advancements in Cancer Treatment

PYXS is renowned for its clinical-stage efforts to bring forth next-generation antibody-drug conjugates (ADC) and monoclonal antibody (mAb) immunotherapies. The company's dedication is centred on addressing the critical need for more effective cancer treatments, targeting malignancies that currently have limited therapeutic options.

Corporate Mission and Vision

Headquartered in the biomedical hub of Cambridge, Massachusetts, Pyxis Oncology's mission is to leverage scientific excellence in order to deliver life-changing treatments to cancer patients. The company's strategy involves a meticulous focus on novel targets and pathways that can potentially transform cancer therapy paradigms.

Expectations from the Conference

The Leerink Global Biopharma Conference provides a significant platform for PYXS to share its vision and progress with a global audience, including industry experts, potential investors, and partners. The participation of Dr. Sullivan is anticipated to spotlight the company's innovative pipeline and the strides it's making in oncology research and development.

Pyxis, Oncology, Conference